Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by JimmyJon Jul 17, 2021 9:25pm
136 Views
Post# 33565887

RE:RE:RE:RE:RE:RE:RE:52 week low

RE:RE:RE:RE:RE:RE:RE:52 week low
Doccole wrote:

I don't mind him as a person, prolly a great guy.  I don't like how this strategy has unfolded.  I am not sure what is up for vote, haven't looked yet, but I will be saying no to any "atta boy" shares and no to things I don't endorse. 



Where do you think the SP would today if the Connacord raise didn't happen back February following the Nuance deal?

We'll never know but based on historical data in this industry, it would gone up maybe to $8 or $10 max, followed by a slow bleed back to these levels guaranteed.  When catalysts are 6-8 months apart, these stocks always drop.  It's the nature of biotech.   It's a damned if you do, more damned if you don't situation for Dan.  He had an opportunity to increase the cash reserve with little impact knowing exactly where the SP was going in the long run this year. It was the right call IMO.  

As sad as it is, this won't be the last time we see a major claw back with this stock.  There will likely be many more before they hit it out of the park.   It's going to be a bumpy ride to get there.   Sit back, buckle up and enjoy.


 

 

<< Previous
Bullboard Posts
Next >>